Clinical trial
A Phase 3, 2-Part, Open-Label and Double-Blind, Randomised Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
NCT06526182 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, 2-Part, Open-Label and Double-Blind, Randomised Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
- Lead sponsor
- Almirall, S.A.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- July 3, 2024
- Completion date
- April 25, 2027
- Enrollment
- 520 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.